Table 2.
Durability of immune responses among vaccine recipients in the per-protocol cohort of HVTN 097.
| Measure1 | Peak timepoint (V143) response rate | Durability timepoint (V174) response rate | McNemar’s test p-value V14 vs V17 (response rate) | Peak timepoint (V14) median magnitude (among V14 responders) | Durability timepoint (V17) median magnitude (among V14 responders) | Durability timepoint median/peak timepoint median | Wilcoxon signed-rank test p-value V14 vs V17 (magnitude) |
|---|---|---|---|---|---|---|---|
| CD4+ Env.92TH023.AE2 | 70.8% | 36.1% | <0.001 | 0.15% T cells expr. IL-2/IFN-γ | 0.07% T cells expr. IL-2/IFN-γ | 46.7% | <0.001 |
| BAMA IgG 92TH023_D11gp120.AE | 100% | 51.5% | <0.001 | 17713.4 MFI-Blank | 176.1 MFI-Blank | 1.0% | <0.001 |
| BAMA IgG A244 D11gp120_avi.AE | 100% | 98.5% | 1 | 20274.8 MFI-Blank | 1098.8 MFI-Blank | 5.4% | <0.001 |
| BAMA IgG Con 6 gp120/B | 100% | 62.7% | <0.001 | 15022.3 MFI-Blank | 372.4 MFI-Blank | 2.5% | <0.001 |
| BAMA IgG MN gp120 gDneg/293F.B | 100% | 20.9% | <0.001 | 9507.4 MFI-Blank | 208.2 MFI-Blank | 2.2% | <0.001 |
| BAMA IgG con_env03 140 CF.A1 | 100% | 7.0% | <0.001 | 1453 MFI-Blank | 17.9 MFI-Blank | 1.2% | <0.001 |
| BAMA IgG 01_con_env03 gp140CF_avi.AE | 100% | 67.2% | <0.001 | 14395.1 MFI-Blank | 251.5 MFI-Blank | 1.8% | <0.001 |
| BAMA IgG Con S gp140 CFI | 100% | 33.3% | <0.001 | 17069.3 MFI-Blank | 449 MFI-Blank | 2.6% | <0.001 |
| BAMA IgG A244 V1V2 Tags/293F.AE | 100% | 62.7% | <0.001 | 25793.7 MFI-Blank | 680.5 MFI-Blank | 2.6% | <0.001 |
| BAMA IgG CaseA2_gp70_V1V2.B | 96.8% | 19.1% | <0.001 | 4145.6 MFI-Blank | 23.5 MFI-Blank | 0.6% | <0.001 |
| BAMA IgG3 92TH023 gp120.AE | 66.7% | 1.4% | <0.001 | 475.8 MFI-Blank | 1.8 MFI-Blank | 0.4% | <0.001 |
| BAMA IgG3 A244 D11gp120_avi.AE | 72.2% | 2.8% | <0.001 | 412 MFI-Blank | 5.1 MFI-Blank | 1.2% | <0.001 |
| BAMA IgG3 Con 6 gp120/B | 62.5% | 0% | <0.001 | 246.9 MFI-Blank | 4.1 MFI-Blank | 1.7% | <0.001 |
| BAMA IgG3 MN gp120 gDneg/293F.B | 70.8% | 1.4% | <0.001 | 741.4 MFI-Blank | 2.8 MFI-Blank | 0.4% | <0.001 |
| BAMA IgG3 con_env03 140 CF.A1 | 9.7% | 0% | 0.016 | 172 MFI-Blank | 3.8 MFI-Blank | 2.2% | 0.016 |
| BAMA IgG3 01_con_env03 gp140CF_avi.AE | 45.8% | 1.4% | <0.001 | 295 MFI-Blank | 3.6 MFI-Blank | 1.2% | <0.001 |
| BAMA IgG3 Con S gp140 CFI | 75.0% | 0% | <0.001 | 348.7 MFI-Blank | 2.1 MFI-Blank | 0.6% | <0.001 |
| BAMA IgG3 A244 V1V2 Tags/293F.AE | 88.9% | 4.2% | <0.001 | 1464.8 MFI-Blank | 6.5 MFI-Blank | 0.4% | <0.001 |
| BAMA IgG3 1086 V2 tags/293F.C | 29.2% | 1.4% | <0.001 | 241.1 MFI-Blank | 9.2 MFI-Blank | 3.8% | <0.001 |
| BAMA IgG3 1086_V1V2_Tags.C | 72.2% | 1.4% | <0.001 | 727 MFI-Blank | 6.6 MFI-Blank | 0.9% | <0.001 |
| BAMA IgG3 CaseA2_gp70_V1V2.B | 28.6% | 0% | <0.001 | 400.9 MFI-Blank | 2.1 MFI-Blank | 0.5% | <0.001 |
| BAMA IgG3 MN V3 gp70.B | 74.3% | 0% | <0.001 | 491.8 MFI-Blank | 1 MFI-Blank | 0.2% | <0.001 |
| BAMA IgG3 gp41 | 5.6% | 5.6% | 1 | 286.6 MFI-Blank | 62 MFI-Blank | 21.6% | 0.125 |
| BAMA IgG3 p24 | 70.8% | 33.8% | <0.001 | 3013.3 MFI-Blank | 177 MFI-Blank | 5.9% | <0.001 |
The clade of the antigen is indicated by the last letter(s) of the name (e.g., 92TH023_D11gp120.AE is clade AE).
This analysis uses 12-color flow cytometric panel originally used for the protocol, whereas the comparisons with RV144 elsewhere in this paper used an updated 16-color panel to match contemporaneous RV144 sample studies.
Visit 14 (V14) corresponds to the peak immunogenicity timepoint (two weeks post second ALVAC/AIDSVAX vaccination).
Visit 17 (V17) corresponds to the durability immunogenicity timepoint (six months post second ALVAC/AIDSVAX vaccination).
MFI-Blank = background-subtracted mean fluorescent intensity (MFI), where background refers to a plate level control (i.e., a blank well run on each plate).